ClinicalTrials.Veeva
Menu

Find clinical trials for Leukemia in London, England

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Myeloid Leukemia
Acute Myeloid Leukemia
Lymphoid Leukemia
B-Cell Chronic Lymphocytic Leukemia
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Lymphoma
Myelodysplastic Syndromes

Leukemia trials near London, England, GBR:

First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia

inhibitor, in patients with relapsed or refractory acute myeloid leukemia (AML) as part of Phase 1. In Phase 2, assessment of ziftomenib wil...

Enrolling
Acute Leukemia of Ambiguous Lineage
Mixed Phenotype Acute Leukemia
Drug: Ziftomenib

Phase 1, Phase 2

Kura Oncology

London, United Kingdom and 51 other locations

Locations recently updated

Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors

this study is to evaluate the safety, tolerability, pharmacokinetics, and efficacy of ponatinib in children aged 1 to \< 18 years with advanced leukemias...

Enrolling
Accelerated Phase Chronic Myeloid Leukemia
Acute Lymphocytic Leukemia
Drug: Ponatinib

Phase 1, Phase 2

Incyte
Incyte

Sutton, United Kingdom and 32 other locations

A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy

with low-dose cytarabine (LDAC) improves overall survival (OS) versus LDAC and placebo, in treatment-naïve patients with acute myeloid leukemia...

Active, not recruiting
Acute Myeloid Leukemia (AML)
Drug: Placebo
Drug: Venetoclax

Phase 3

AbbVie
AbbVie

Harrow, United Kingdom and 108 other locations

ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia

This study is evaluating the safety and efficacy of a new BTK inhibitor, acalabrutinib, for the treatment of chronic lymphocytic leukemia (C...

Active, not recruiting
Chronic Lymphocytic Leukemia
Prolymphocytic Leukemia
Drug: Acalabrutinib

Phase 1, Phase 2

Acerta Pharma
Acerta Pharma

London, United Kingdom and 11 other locations

Phase I/II Trial of S65487 Plus Azacitidine in Acute Myeloid Leukemia

The purpose of this study is to assess the safety, tolerability and clinical activity of the combination S65487 with azacitidine in patients with acu...

Active, not recruiting
Acute Myeloid Leukemia
Drug: S65487 and azacitidine

Phase 1, Phase 2

Servier
Servier

London, United Kingdom and 10 other locations

Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses (OPTIC)

The purpose of this study is to characterize the efficacy of ponatinib administered in 3 starting doses (45 mg, 30 mg, and 15 mg daily) in participan...

Active, not recruiting
Myeloid Leukemia, Chronic, Chronic Phase
Drug: Ponatinib

Phase 2

Takeda
Takeda

London, England, United Kingdom and 85 other locations

A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) (ASC4START)

of asciminib versus nilotinib for the treatment of newly diagnosed, previously untreated patients with Positive Chronic Myelogenous Leukemia...

Active, not recruiting
Philadelphia Chromosome-Positive Chronic Myeloid Leukemia
Drug: Nilotinib
Drug: Asciminib

Phase 3

Novartis
Novartis

London, United Kingdom and 120 other locations

A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation

with FMS-like tyrosine kinase (FLT3) mutated acute myeloid leukemia (AML) who are refractory to or have relapsed after first-line AML therap...

Active, not recruiting
Leukemia, Acute Myeloid (AML)
Drug: MEC (Mitoxantrone, Etoposide, Cytarabine)
Drug: gilteritinib

Phase 3

Astellas
Astellas

Harrow, United Kingdom and 125 other locations

A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy

of the combinations of AG-120 with azacitidine and AG-221 with azacitidine versus with azacitidine alone in participants with acute myeloid leukemia...

Active, not recruiting
Leukemia, Myeloid, Acute
Drug: Azacitidine
Drug: AG-120

Phase 1, Phase 2

Celgene
Celgene

London, United Kingdom and 48 other locations

Study to Evaluate Safety and Tolerability of CC-91633 (BMS-986397) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes

in participants with relapsed or refractory acute myeloid leukemia (R/R AML) or in participants with relapsed or refractory higher-risk myel...

Enrolling
Leukemia, Myeloid, Acute
Myelodysplastic Syndromes
Drug: CC-91633

Phase 1

Celgene
Celgene

London, United Kingdom and 28 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2025 Veeva Systems